Cargando…

Clinical relevance of single item quality of life indicators in cancer clinical trials

We investigated the hypothesis that global single-item quality-of-life indicators are less precise for specific treatment effects (discriminant validity) than multi-item scales but similarly efficient for overall treatment comparisons and changes over time (responsiveness) because they reflect the s...

Descripción completa

Detalles Bibliográficos
Autores principales: Bernhard, J, Sullivan, M, Hürny, C, Coates, A S, Rudenstam, C-M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363885/
https://www.ncbi.nlm.nih.gov/pubmed/11336464
http://dx.doi.org/10.1054/bjoc.2001.1785
_version_ 1782153816001478656
author Bernhard, J
Sullivan, M
Hürny, C
Coates, A S
Rudenstam, C-M
author_facet Bernhard, J
Sullivan, M
Hürny, C
Coates, A S
Rudenstam, C-M
author_sort Bernhard, J
collection PubMed
description We investigated the hypothesis that global single-item quality-of-life indicators are less precise for specific treatment effects (discriminant validity) than multi-item scales but similarly efficient for overall treatment comparisons and changes over time (responsiveness) because they reflect the summation of the individual meaning and importance of various factors. Linear analogue self-assessment (LASA) indicators for physical well-being, mood and coping were compared with the Hospital Anxiety and Depression Scale (HAD), the Mood Adjective Check List (MACL) and the emotional behaviour and social interaction scales of the Sickness Impact Profile (SIP) in 84 patients with early breast cancer receiving adjuvant therapy. Discriminant validity was investigated by multitrait-multimethod correlation, responsiveness by standardized response mean (SRM). Discriminant validity of the indicators was present at baseline but less under treatment. Responsiveness was demonstrated by the expected pattern among treatments (P = 0.008). In patients without chemotherapy, the SRMs indicated moderate (0.5–0.8) to large (>0.8) improvements in physical well-being (0.70), coping (0.92), HAD anxiety (0.89) and depression (1.19), and MACL mental well-being (0.68). In patients with chemotherapy for the first 3 months, small but clinically significant improvements (>).2) included mood (0.38), coping (0.41), HAD axiety (0.31) and MACL mental well-being (0.35). Patients with 6 months chemotherapy showed no changes. The indicators also reflected mood disorders (HAD) and marked psychosocial dysfunction (SIP) at baseline and under treatment according to pre-defined cut-off levels. Global indicators were confirmed to be efficient for evaluating treatments overall and changes over time. The lower reliability of single as opposed to multi-item scales affects primarily their discriminant validity. This is less decisive in large sample sizes. © 2001 Cancer Research Campaign http://www.bjcancer.com
format Text
id pubmed-2363885
institution National Center for Biotechnology Information
language English
publishDate 2001
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23638852009-09-10 Clinical relevance of single item quality of life indicators in cancer clinical trials Bernhard, J Sullivan, M Hürny, C Coates, A S Rudenstam, C-M Br J Cancer Regular Article We investigated the hypothesis that global single-item quality-of-life indicators are less precise for specific treatment effects (discriminant validity) than multi-item scales but similarly efficient for overall treatment comparisons and changes over time (responsiveness) because they reflect the summation of the individual meaning and importance of various factors. Linear analogue self-assessment (LASA) indicators for physical well-being, mood and coping were compared with the Hospital Anxiety and Depression Scale (HAD), the Mood Adjective Check List (MACL) and the emotional behaviour and social interaction scales of the Sickness Impact Profile (SIP) in 84 patients with early breast cancer receiving adjuvant therapy. Discriminant validity was investigated by multitrait-multimethod correlation, responsiveness by standardized response mean (SRM). Discriminant validity of the indicators was present at baseline but less under treatment. Responsiveness was demonstrated by the expected pattern among treatments (P = 0.008). In patients without chemotherapy, the SRMs indicated moderate (0.5–0.8) to large (>0.8) improvements in physical well-being (0.70), coping (0.92), HAD anxiety (0.89) and depression (1.19), and MACL mental well-being (0.68). In patients with chemotherapy for the first 3 months, small but clinically significant improvements (>).2) included mood (0.38), coping (0.41), HAD axiety (0.31) and MACL mental well-being (0.35). Patients with 6 months chemotherapy showed no changes. The indicators also reflected mood disorders (HAD) and marked psychosocial dysfunction (SIP) at baseline and under treatment according to pre-defined cut-off levels. Global indicators were confirmed to be efficient for evaluating treatments overall and changes over time. The lower reliability of single as opposed to multi-item scales affects primarily their discriminant validity. This is less decisive in large sample sizes. © 2001 Cancer Research Campaign http://www.bjcancer.com Nature Publishing Group 2001-05 /pmc/articles/PMC2363885/ /pubmed/11336464 http://dx.doi.org/10.1054/bjoc.2001.1785 Text en Copyright © 2001 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Bernhard, J
Sullivan, M
Hürny, C
Coates, A S
Rudenstam, C-M
Clinical relevance of single item quality of life indicators in cancer clinical trials
title Clinical relevance of single item quality of life indicators in cancer clinical trials
title_full Clinical relevance of single item quality of life indicators in cancer clinical trials
title_fullStr Clinical relevance of single item quality of life indicators in cancer clinical trials
title_full_unstemmed Clinical relevance of single item quality of life indicators in cancer clinical trials
title_short Clinical relevance of single item quality of life indicators in cancer clinical trials
title_sort clinical relevance of single item quality of life indicators in cancer clinical trials
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363885/
https://www.ncbi.nlm.nih.gov/pubmed/11336464
http://dx.doi.org/10.1054/bjoc.2001.1785
work_keys_str_mv AT bernhardj clinicalrelevanceofsingleitemqualityoflifeindicatorsincancerclinicaltrials
AT sullivanm clinicalrelevanceofsingleitemqualityoflifeindicatorsincancerclinicaltrials
AT hurnyc clinicalrelevanceofsingleitemqualityoflifeindicatorsincancerclinicaltrials
AT coatesas clinicalrelevanceofsingleitemqualityoflifeindicatorsincancerclinicaltrials
AT rudenstamcm clinicalrelevanceofsingleitemqualityoflifeindicatorsincancerclinicaltrials